TENX · Tenax Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | $0 | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $11.54M | - | $10.33M | $6.12M | $5.68M | - | $3.11M | $2.33M | $2.68M | - |
| SG&A | $5.03M | - | $6.48M | $5.67M | $5.66M | - | $1.51M | $1.34M | $1.23M | - |
| Total Operating Expenses | $16.57M | - | $16.81M | $11.79M | $11.34M | - | $4.62M | $3.67M | $3.91M | - |
| D&A | - | - | - | - | - | - | $0 | $1.0K | $0 | - |
| Operating Income | ($16.57M) | - | ($16.81M) | ($11.79M) | ($11.34M) | - | $4.62M | $3.67M | ($3.91M) | - |
| Interest Expense | - | - | - | - | $0 | - | $6.3K | $9.2K | $8.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($15.72M) | - | ($15.80M) | ($10.85M) | ($10.41M) | - | $3.96M | $3.58M | $3.80M | - |
| EPS - Basic | ($0.35) | - | ($0.19) | ($1.83) | ($3.12) | - | - | - | - | - |
| EPS - Diluted | ($0.35) | - | ($0.40) | ($0.27) | ($3.12) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $118.80M | $97.60M | $99.40M | $105.50M | $111.40M | $94.90M | $98.31M | $9.38M | $12.55M | $9.80M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.35M | $6.04M | $5.61M | $562.0K | $1.84M | $3.16M | $1.58M | $869.7K | $1.08M | $2.07M |
| Current Assets | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M | $99.78M | $10.62M | $14.46M | $11.68M |
| Total Assets | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M | $99.78M | $10.62M | $14.46M | $11.68M |
| Current Liabilities | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M | $2.56M | $1.74M | $2.03M | $3.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M | $2.56M | $1.74M | $2.03M | $3.59M |
| Stockholders' Equity | $114.69M | $97.07M | $96.21M | $103.33M | $109.29M | $91.99M | $97.22M | $8.88M | $12.43M | $8.10M |
| Retained Earnings | ($383.17M) | ($367.45M) | ($351.91M) | ($336.11M) | ($325.26M) | ($314.86M) | ($308.59M) | ($304.63M) | ($301.05M) | ($297.25M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.31M) | - | - | - | ($5.17M) | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $0 | - |
| Financing Cash Flow | $30.50M | - | - | - | $23.56M | - | - | - | $7.92M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.8% | - | -15.4% | -10.2% | -9.3% | - | 4.0% | 33.7% | 26.3% | - |
| Return on equity | -13.7% | - | -16.4% | -10.5% | -9.5% | - | 4.1% | 40.3% | 30.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 14.52 | 14.56 | 15.58 | 41.89 | 40.48 | 20.60 | 38.95 | 6.10 | 7.12 | 3.26 |
| Quick ratio | 14.52 | 14.56 | 15.58 | 41.89 | 40.48 | 20.60 | 38.95 | 6.10 | 7.12 | 3.26 |
| Cash ratio | 14.00 | 13.64 | 15.06 | 41.75 | 40.25 | 20.22 | 38.38 | 5.39 | 6.18 | 2.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | 731.8x | 399.6x | -490.8x | - |
| Equity multiplier | 1.07 | 1.07 | 1.07 | 1.02 | 1.03 | 1.05 | 1.03 | 1.20 | 1.16 | 1.44 |
| Liabilities / Assets | 0.07 | 0.07 | 0.06 | 0.02 | 0.02 | 0.05 | 0.03 | 0.16 | 0.14 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.3x | - | 1.7x | 0.1x | 0.1x | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -46.2% | - | - | - | -190.1% | - | 118.1% | 197.1% | - | - |
| Net income growth (YoY) | -51.0% | - | - | - | - | - | 100.8% | - | 170.0% | - |
| EPS growth (YoY) | 88.8% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 4.9% | 5.5% | -1.0% | 1064.1% | 779.3% | 1036.0% | 761.4% | -32.9% | -12.9% | 442.5% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing TENAX THERAPEUTICS against the 5 most active filers in the same SIC group.